FASLG and neoplasm: Notably, VEGF-A, interleukin 10 (IL-10) and prostaglandin E2 (PGE2) are involved in eliciting FasL expression in endothelial cells, as evidenced by observations that pharmacological inhibition of these molecules leads to a marked influx of tumor-rejecting CD8+ cells and tumor growth suppression in mice.